Evidence map›Paper›PMID 41711962›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

Association of patient factors and health-related quality of life with weight changes during chemotherapy for colorectal cancer: secondary analysis of the SCOT trial.

T S Varghese, S Faithfull, A Frampton, A Harkin, T Iveson, C Kelly, M E Phillips, M P Saunders, A Lemanska

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

T S VargheseFaculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
S FaithfullTrinity St. James's Cancer Institute, Trinity College Dublin, Dublin, Ireland.
A FramptonFaculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
A HarkinGlasgow Oncology Clinical Trials Unit, University of Glasgow, Glasgow, UK.
T IvesonDepartment of Medical Oncology, University of Southampton, Southampton, UK.
C KellyGlasgow Oncology Clinical Trials Unit, University of Glasgow, Glasgow, UK.
M E PhillipsFaculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
M P SaundersThe Christie, Manchester, UK.
A LemanskaImperial Clinical Trials Unit, Imperial College London, London, UK. a.lemanska@imperial.ac.uk.

Funding

EPSRC DTC PhD studentship EP/T518050/1
6 · The paper itself

Abstract

purposeTo investigate patterns of weight change during chemotherapy for colorectal cancer and analyse their associations with patient demographic, clinical factors, and health-related quality of life (HRQoL).

methodsWe performed secondary analysis of data from 2,871 participants of the SCOT randomised controlled trial. SCOT compared 3 months to 6 months of adjuvant oxaliplatin-containing chemotherapy in people with colorectal cancer. HRQoL was measured with EQ-5D-3L. Mean changes in weight over time were plotted with 95% confidence intervals (CIs) and analysed stratified by sex, chemotherapy regimen and duration. Associations with patient characteristics were evaluated using multivariable linear regression.

resultsThe median age of participants was 65 (interquartile range was 59 to 70), 38.7% were female and 95.8% of participants were white. Male participants gained on average 1.2 kg (95% CI 1.0 to 1.4), and females gained 0.8 kg (95% CI 0.6 to 1.1). By the end of treatment, 161 (6.1%) participants shifted from body mass index (BMI) < 25 kg/m

conclusionsYounger patients, males, and those with higher HRQoL experienced greater weight gain during chemotherapy for colorectal cancer, emphasising the need to monitor and manage body weight to prevent increase in obesity during curative treatment.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsQuality of LifeWeight GainAgedBody Mass IndexChemotherapy, AdjuvantFemaleHumansLinear ModelsMaleMiddle AgedOxaliplatinSex FactorsOxaliplatinChemotherapyColorectal cancerOxaliplatinWeight changesWeight gainWeight loss

Identifiers

PMID41711962
PMCPMC12920390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.